INTRODUCTION
============

Intramedullary spinal cord metastasis (ISCM) is a rare complication of cancer, affecting 0.1%-0.4% of all cancer patients \[[@B1], [@B2]\]. It accounts for 2%-8.5% of central nervous system (CNS) metastases and 0.9%-5% of all spinal cord metastases. ISCM arises most commonly from small-cell lung cancer, but can also be seen in non-small-cell lung cancer, breast cancer, kidney cancer, melanoma, and lymphoma \[[@B2]\]. Until now, colorectal-cancer-related ISCM has been extremely rare, with only a few cases reported in the literature \[[@B2], [@B3]\]. In Korea, colorectal-cancer-related ISCM has not been reported yet.

The most common symptom of ISCM is a rapidly progressive neurologic deficit. The overall prognosis is reported to be very poor; half of patients with ISCM die in the 3-4 months after the appearance of the first symptom \[[@B1], [@B2], [@B3]\]. However, in recent years, due to progress in diagnostic imaging, microsurgical techniques, and radiotherapy, the duration of survival and the quality of life have improved because of early detection and prompt management, even in patients with ISCM \[[@B1], [@B2]\].

We report on a patient with an intramedullary metastasis from advanced rectal cancer coexisting with lung metastases and diagnosed by magnetic resonance imaging (MRI). Our case is the first report of ISCM arising from colorectal cancer in Korea.

CASE REPORT
===========

A 75-year-old man came to the hospital, complaining of left-foot drop and numbness in both legs that had appeared 3 days before. He also had left lower leg and foot pain. He had no recent history of trauma in the legs. The symptoms progressed rapidly over 3 days. The patient had been diagnosed with rectal cancer 4 years earlier, which was found on the proximal 2.5 cm from the anal verge. At that time, colonoscopic biopsy confirmed a moderately-differentiated adenocarcinoma; the patient underwent neoadjuvant chemoradiation therapy, followed by Mile\'s surgery. During surgery, a pathological specimen showed no residual tumor on the anus and distal rectum; however, submucosal fibrosis, reactive epithelial changes, and acellular mucin pools were seen. No lymph-node metastases were found in 20 regional lymph nodes (0/20). The patient had maintained a disease-free status after surgery, but 20 months after the operation, multiple metastatic nodules of the lung were found on computed tomography of the chest ([Fig. 1](#F1){ref-type="fig"}). He was treated with palliative chemotherapy with FOLFOX regimen (5-FU, oxaliplatin, leucovorin). Even after first line chemotherapy, his disease did not improve. Thus, the chemotherapeutic regimen was switched to the second line, capecitabine. After 4 months, multiple metastatic nodules grew again, and new nodules were found in the patient\'s lungs. We changed the chemotherapeutic regimen again to FOLFIRI (5-FU, irinotecan, leucovorin). The lung metastatic nodules responded to third line chemotherapy; however, they decreased rather than disappearing. His disease maintained a stable status over 11 months, after which it no longer responded to chemotherapy and continued to progress. While the patient was receiving supportive care, the symptoms of left-foot drop and numbness in both lower legs developed suddenly.

On physical examination, the patient had left dominant lower-extremity motor weakness (left leg motor, Gr2; right leg motor, Gr4) while his upper-extremity muscle power was intact. He felt numbness in the left leg and the right leg, extending to the left hip and the right knee. He exhibited an absence of deep tendon reflex on both knee joints and both ankle joints. He had pain in his left foot, along with the foot drop. A thoracolumbar MRI revealed a peripheral enhanced intramedullary nodular lesion (0.9 cm × 0.9 cm × 2.8 cm) at the T12 level and diffuse spinal-cord signal change with a bulging contour at the thoracic spine level, suggesting diffuse intramedullary metastasis or secondary change due to a mass on the T12 spine ([Fig. 2](#F2){ref-type="fig"}). A cerebrospinal fluid (CSF) analysis showed no abnormal findings, and CSF cytology was negative. The patient was immediately treated with steroids and radiation therapy (39 Gy in 13 fractions) to relieve his symptoms. His symptoms improved for awhile after this treatment; however, his condition deteriorated progressively, and he finally became unconscious. He died 4 months after the ISCM had been diagnosed.

DISCUSSION
==========

ISCM arising from colorectal cancer is extremely rare, and only 12 cases have been reported so far in the literature in English \[[@B4], [@B5], [@B6]\]. Moreover, to the best of our knowledge, colorectal-cancer-related ISCM has not yet been reported in Korea. According to one Korean publication, ISCM was found in 12 cases from 1995 to 2006, but all 12 ISCMs arose from breast cancer or lung cancer \[[@B1]\].

Three pathological mechanisms have been suggested for ISCM \[[@B2], [@B3]\]. Hematogenous spread is believed to be the most common spread route, as the common coexistence of pulmonary metastasis and brain metastasis in ISCM patients supports the possibility of spread through an arterial route \[[@B2], [@B3]\]. Therefore, dissemination through arterial routes from the carcinoma with adjacent vessels has been speculated to be a major mechanism for hematogenous spread \[[@B2], [@B7]\]. Another hematogenous spread route is considered to be the vertebral venous plexus, extending from the pelvis to the cranial venous sinuses \[[@B1], [@B4]\]. This second mechanism is associated with meningeal seeding. Tumor cells from carcinomatous meningitis may infiltrate the vessels, penetrate the spinal cord, and eventually invade the spinal-cord parenchyma \[[@B2]\]. The third mechanism is related to dissemination though direct extension of a metastatic tumor from the spinal extradural space, CSF, and nerve roots \[[@B2]\].

The fact that this patient had multiple pulmonary metastatic nodules and negative CSF findings suggests that ISCM in this patient could have resulted from hematogenous dissemination. In a report by Ogino et al. \[[@B8]\], four of eight colorectal-related ISCM cases exhibited lung metastasis, indicating that colon cancer patients with lung metastasis had a higher risk of ISCM than those without it. Patients with ISCM are usually in an advanced state of the disease with other metastases. In particular, 25%-60% of patients with a brain metastasis showed ISCM at the time of diagnosis \[[@B2], [@B3], [@B9]\]. In contrast, in several studies, patients with other vertebral metastases were observed to have few brain metastases \[[@B2]\]. That our patient had a brain metastasis was not clear at the time ISCM was diagnosed because a work-up for brain metastasis had not been performed. However, he did not show any symptoms or signs of a brain metastasis when ISCM was diagnosed.

The clinical presentation of ISCM arises from symptoms of spinal-cord invasion. Because the clinical features of cord compression and cord invasion are very similar \[[@B2]\], distinguishing a intramedullary metastasis from an extradural spinal metastasis through clinical presentation alone is difficult. Weakness and numbness are the most common symptoms of ISCM \[[@B1], [@B2], [@B10]\]. Weakness is presented in 91% of ISCM patients while 82% of such patients exhibit numbness. The duration of symptoms before diagnosis ranges widely, from 1 day to 2 years (median, 52 days) \[[@B2]\]. This patient presented with left-foot drop and numbness in both lower legs that had lasted for 3 days.

Currently, ISCM is mainly diagnosed through an imaging study. MRI has high sensitivity when it comes to identifying spine lesions \[[@B2]\]. Therefore, MRI should be recommended for a cancer patient who presents with a sudden onset of motor weakness, sensory loss, or severe back pain. According to several studies, positron emission tomography (PET) is helpful in diagnosing ISCM. When MRI is contraindicated, PET may be considered as an option to evaluate the presence of this condition \[[@B11]\]. Histological confirmation may not be necessary because imaging studies have high sensitivity and many patients with ISCM exhibit poor performance status. We were able to diagnose this patient as having ISCM via MRI.

ISCM has a very poor prognosis. The mean survival after diagnosis is reported to be 3 months, and the median survival of these patients is limited to 3-7 months \[[@B2], [@B3], [@B5]\]. Our patient survived for 4 months after the ISCM had been found. Unfortunately, a guideline for ISCM treatment has not been established because ISCM is a rare complication in cancer patients \[[@B2], [@B7]\]. Surgical resection can be considered in selected cases. The therapist must consider several factors, including general performance, medical condition, tumor size, number of tumors, and leptomeningeal metastasis. The survival time of patients treated with a surgical resection was reported to be nearly two times that of other patients \[[@B2]\]. Because those patients exhibited good performance and medical status, a surgical resection may be considered as an option for patients with a single ISCM and good performance status. In other cases, more conservative approaches, such as radiation therapy, steroids, and chemotherapy, can be applied for ISCM patients to improve their quality of life. In patients treated with conservative measures, 50% improve, 28% exhibit no change, and 22% deteriorate. In patients who undergo a surgical resection, improvement is seen in 77% of the cases and no change in 23% \[[@B7]\]. Steroid therapy is not considered a single treatment and has no additional survival benefit \[[@B2], [@B5]\]. However, in patients with rapidly-progressive symptoms of cord compression, it may decrease pain and neurological dysfunction \[[@B12]\]. Chemotherapy has been used in combination with radiotherapy or surgical resection in some chemosensitive tumors, such as small-cell carcinomas and hematological malignancies \[[@B7], [@B13]\]. Radiation therapy has been the treatment of choice in many advanced ISCM cases, as this can suppress the tumor and slow down the progression of neurological symptoms. The best responses can be observed in radiosensitive tumors if treated very early in the course of presentation. However, such an approach would be ineffective in radio-resistant tumors \[[@B5]\]. In a recent study, after radiotherapy, 10 of 18 patients (56%) exhibited improvement in neurological deficits or relief from pain, but none achieved complete remission \[[@B5]\]. In several reports, radiation therapy of 20 Gy in 5 fractions to 40 Gy in 20 fractions was used \[[@B1], [@B5], [@B14]\]. Our patient was also treated with radiation therapy with steroids. This seemed to be effective for awhile, but his symptoms deteriorated progressively, and he ultimately died. Nevertheless, because few patients can undergo a surgical resection, radiation therapy is considered to be an important treatment for ISCM.

In conclusion, this report suggests that when a patient with metastasis on the lung or brain complains of neurological symptoms, the rare condition of ISCM should be considered. MRI and/or PET can help to diagnose ISCM. Treatment may involve surgical resection, radiotherapy, or chemotherapy. Regardless of treatment, the prognosis for patients with ISCM is very poor.

No potential conflict of interest relevant to this article was reported.

![Chest computed tomography (CT): an axial view (A) and a coronal view (B) on chest CT, showing multiple metastases on both lungs.](ac-30-237-g001){#F1}

![Spine magnetic resonance imaging: (A) T2-weighted view showing solitary intramedullary nodular lesion at the T12 level and (B) contrast-enhanced T1-weighted image in the patient, indicating an intramedullary lesion with a peripheral enhancing pattern at the T12 level (The arrow indicates the ISCM lesion).](ac-30-237-g002){#F2}
